Share chart Immunic, Inc.
Extended chart
Simple chart
About Immunic, Inc.
Immunic, Inc., биофармацевтическая компания, работающая на клинической стадии, разрабатывает серию селективных пероральных иммунологических методов лечения хронических воспалительных и аутоиммунных заболеваний. Его ведущая программа разработки - IMU-838, которая находится в клинической фазе 2 для лечения ремиттирующего рассеянного склероза, воспалительного заболевания кишечника и других хронических воспалительных и аутоиммунных заболеваний, а также для лечения коронавирусной болезни. more detailsMain settings
IPO date
2014-04-17
ISIN
US4525EP1011
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0 | 0 |
| P/BV | 2.21 | 7 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -172.4 | 0 |
| ROE | -323.57 | 0 |
| ROIC | -57.1 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0135 | 10 |
| Debt/Ratio | 0.0246 | 10 |
| Debt/Equity | 0.8768 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 168 | 10 |
| Yield EPS, % | -53.27 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 0.918 $ | 0 $ | 0 $ | -0.04 % | 0 % | 0 % |
| Week | 0.961 $ | 0 $ | 0 $ | -4.52 % | 0 % | 0 % |
| Month | 1.14 $ | 0.9176 $ | 1.02 $ | -19.51 % | 0 % | 0 % |
| Three month | 1.2 $ | 0.884 $ | 1.28 $ | -23.53 % | 0 % | 0 % |
| Half a year | 1.14 $ | 0.884 $ | 1.32 $ | -19.51 % | 0 % | 0 % |
| Year | 1.25 $ | 0.884 $ | 1.95 $ | -26.59 % | 0 % | 0 % |
| 3 years | 3.8 $ | 0.884 $ | 10.03 $ | -75.85 % | 0 % | 0 % |
| 5 years | 13.85 $ | 0.884 $ | 21.91 $ | -93.37 % | 0 % | 0 % |
| 10 years | 0 $ | 0.17 $ | 1 032.8 $ | 0 % | 0 % | 0 % |
| Year to date | 1 $ | 0.884 $ | 1.28 $ | -8.24 % | 0 % | 0 % |
Main owners
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Hella Kohlhof | Chief Scientific Officer | N/A | 1974 (51 year) |
| Jessica Breu | Head of Investor Relations & Communications | N/A | |
| Mr. Inderpal Singh | General Counsel | N/A | 1967 (58 years) |
| Mr. Patrick Walsh | Chief Business Officer | N/A | 1984 (41 year) |
| Mr. Glenn Whaley CPA | Chief Financial Officer | 522.21k | 1968 (57 years) |
| Dr. Andreas Muehler M.D., Ph.D. | Chief Medical Officer | 599.57k | 1965 (60 years) |
| Dr. Daniel Vitt Ph.D. | CEO & Director | 728.4k | 1968 (57 years) |
| Dr. Duane D. Nash J.D., M.B.A., M.D. | Executive Chairman | 433.4k | 1971 (54 years) |
| Mr. Jason Tardio M.B.A. | COO & President | 1977 (48 years) | |
| Mr. Werner Gladdines | Chief Development Officer |
About company
Address: United States, New York, 1200 Avenue of the Americas - Open in google maps, Open in yandex maps
Website: http://www.immunic-therapeutics.com
Website: http://www.immunic-therapeutics.com
